Clinical Trials Logo

Gastric Ulcers clinical trials

View clinical trials related to Gastric Ulcers.

Filter by:
  • None
  • Page 1

NCT ID: NCT01456260 Completed - Gastric Ulcers Clinical Trials

Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Start date: September 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety of TAK-438, once daily (QD), during long-term concomitant non-steroidal anti-inflammatory drug (NSAID) therapy in patients with a history of gastric or duodenal ulcer who require long-term therapy of NSAID.

NCT ID: NCT01456247 Completed - Gastric Ulcers Clinical Trials

Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Start date: March 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety of TAK-438, once daily (QD), during long-term concomitant low-dose aspirin therapy in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.

NCT ID: NCT01452763 Completed - Gastric Ulcers Clinical Trials

Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Start date: October 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD) compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.

NCT ID: NCT01452750 Completed - Gastric Ulcers Clinical Trials

Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Start date: October 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD), compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of non-steroidal anti-Inflammatory drug (NSAID).